clinical trial · NCT07818967
A Study of Abemaciclib (LY2835219) in Healthy Participants
Eli Lilly and Company·phase1·recruiting·n = 15
Healthy VolunteersAbemaciclib Tablet (Test Formulation)Abemaciclib Tablet (Reference Formulation)Abemaciclib Oral Granules (Test Formulation)
brief summary
The main purpose of this study is to compare different forms of abemaciclib (LY2835219) to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. For each participant, the study will last about 12 weeks and will include 3 stays in the Clinical Research Unit (CRU). Each stay will last 10 days.
started
Sep 2, 2026
primary completion
Nov 1, 2026
completion
Nov 1, 2026
last updated
Sep 23, 2026
official title
A Phase 1, Open-Label, Randomized, Crossover Study to Investigate the Relative Bioavailability of Abemaciclib (LY2835219) Test and Reference Formulations and an Alternate Administration Method, in Healthy Participants.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol